NCT05012670View on ClinicalTrials.gov

Mass Balance Recovery, Metabolite Profile, and Metabolite Identification of [14C]-Paxalisib in Healthy Male Subjects

PHASE1CompletedINTERVENTIONAL
Enrollment

6

Participants

Timeline

Start Date

August 18, 2021

Primary Completion Date

March 30, 2023

Study Completion Date

January 30, 2024

Conditions
Healthy
Interventions
DRUG

[14C]-Paxalisib Capsule

Each subject will receive a single dose 15 mg (NMT 3.5 MBq), administered orally in the fasted state with with 240 mL water.

Trial Locations (1)

NG11 6JS

Quotient Sciences, Nottingham

Sponsors
All Listed Sponsors
collaborator

Quotient Sciences

INDUSTRY

lead

Kazia Therapeutics Limited

INDUSTRY

NCT05012670 - Mass Balance Recovery, Metabolite Profile, and Metabolite Identification of [14C]-Paxalisib in Healthy Male Subjects | Biotech Hunter | Biotech Hunter